Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY: TEVA )

16.80 -0.20 (-1.21%)
Streaming Delayed Price Updated: 12:07 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
26 27 Next >
Teva Pharma's Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q2 sales reached $3.88 billion, up 2% Y/Y (4% on constant currency), slightly beating the  
Via Benzinga
Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And Raise
The company also raised the lower boundary of its guidance for full-year sales. 
Via Investor's Business Daily
Teva Reports Second Quarter 2023 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
From Teva Pharmaceutical Industries Limited
Via Business Wire
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
3 Bargain Stocks to Buy on the Dip
These stocks should be poised to rebound. 
Via The Motley Fool
Why Teva Pharmaceutical Stock Is Jumping Today
Investors are reacting positively to Teva's new growth strategy. 
Via The Motley Fool
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
Via Benzinga
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva's Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.  
Via Benzinga
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
Geopolitical Risks Prevail
A discussion about current geopolitical risks and their impact on commodity and stock markets. 
Via Talk Markets
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients... 
Via Benzinga
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March.  Methotrexate is an injected medication utilized to treat... 
Via Benzinga
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
Teva Concludes Nationwide Opioids Settlement Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
From Phil Inc.
Via Business Wire
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
It's unclear whether the pivot will be enough to halt its recent decline. 
Via The Motley Fool
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
Via Benzinga
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.